Stock BMEA BIOMEA FUSION, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Biomea Fusion, Inc.

Equities

BMEA

US09077A1060

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-24 pm EDT 		5-day change 1st Jan Change
10.77 USD -1.91% Intraday chart for Biomea Fusion, Inc. -6.35% -25.83%
Apr. 03 North American Morning Briefing : Powell Awaited -2- DJ
Apr. 02 Biomea Fusion Shares Decline Following JPMorgan Downgrade MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
North American Morning Briefing : Powell Awaited -2-
DJ
Biomea Fusion Shares Decline Following JPMorgan Downgrade
MT
JPMorgan Downgrades Biomea Fusion to Neutral From Overweight, Adjusts Price Target to $14 From $51
MT
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(4)
AQ
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GL
Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219
GL
Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219
AQ
Biomea Fusion, Inc. Announces Initial Response Data from the First Two Type 1 Diabetes Patients Treated with Bmf-219 in the Ongoing Phase Ii Study (Covalent-112)
CI
Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
GL
Biomea Fusion, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
North American Morning Briefing : Tech in Focus on -2-
DJ
Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219's 28-Day Treatment Cycle
AQ
Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219’s 28-Day Treatment Cycle, Supporting Improved Pancreatic Function
GL
Biomea Fusion, Inc. Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219?s 28-Day Treatment Cycle, Supporting Improved Pancreatic Function
CI
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(4)
AQ
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GL
Truist Securities Starts Biomea Fusion With Buy Rating, $55 Price Target
MT
Biomea Fusion Highlights Recent Updates and Anticipated 2024 Corporate Milestones at 42nd Annual J.P. Morgan Healthcare Conference
GL
Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase II Study with BMF-219
AQ
Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase II Study (COVALENT-112) with BMF-219
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BMEA Stock
  4. News Biomea Fusion, Inc.